Doxapram stimulates carotid body with different mechanisms from hypoxic chemotransduction.
Takahashi
Toru
T
First Department of Medicine, Asahikawa Medical College 2-1-1-1 Midorigaoka Higashi, Asahikawa 078-8510, Japan.
Osanai
Shinobu
S
Nakano
Hitoshi
H
Ohsaki
Yoshinobu
Y
Kikuchi
Kenjiro
K
D000818:Animals; D001562:Benzimidazoles / Q000494:pharmacology; D002344:Carotid Body / Q000187:drug effects* / Q000378:metabolism* / Q000503:physiopathology; D002628:Chemoreceptor Cells / Q000187:drug effects* / Q000378:metabolism* / Q000503:physiopathology; D004315:Doxapram / Q000494:pharmacology*; D004594:Electrophysiology; D006221:Halothane / Q000494:pharmacology; D000860:Hypoxia / Q000378:metabolism* / Q000503:physiopathology; D066298:In Vitro Techniques; D008297:Male; D009419:Nerve Tissue Proteins / Q000187:drug effects / Q000378:metabolism; D015221:Potassium Channels / Q000187:drug effects / Q000378:metabolism; D024683:Potassium Channels, Tandem Pore Domain; D011817:Rabbits
D001562:Benzimidazoles; D009419:Nerve Tissue Proteins; D015221:Potassium Channels; D024683:Potassium Channels, Tandem Pore Domain; C086491:NS 1619; C420132:potassium channel subfamily K member 3; D004315:Doxapram; D006221:Halothane